The State of Monoclonal Antibodies in Medicine Today

Once again, the journal mAbs has published its 11th annual “Antibodies to Watch” article as an overview of exciting antibody products staged for significant advances in the coming year, authored…

Comments Off on The State of Monoclonal Antibodies in Medicine Today

Determining Priorities When Looking for a CDMO

Chamow & Associates is pleased to present a blog series detailing best practices for working with a contract development and manufacturing organization (CDMO). This series is intended to provide a…

Comments Off on Determining Priorities When Looking for a CDMO

Reasons to Use a CDMO

Chamow & Associates is pleased to present a blog series detailing best practices for working with a contract development and manufacturing organization (CDMO). This series is intended to provide a potential…

Comments Off on Reasons to Use a CDMO

Prestigious Medical Research Award Goes to Herceptin

Monoclonal antibodies (mAbs) as a therapeutic modality were developed over an 11-year period, from the first production of mAbs in 1975 to the first licensing of mAb therapeutic Orthoclone OKT3…

Comments Off on Prestigious Medical Research Award Goes to Herceptin

Ebola infection is curable—A phenomenal breakthrough

After the 2014 Ebola outbreak in West Africa, researchers wanted to test ZMapp, a new, experimental drug that had been used during that outbreak on some infected patients, along with…

Comments Off on Ebola infection is curable—A phenomenal breakthrough

Predicting Immunogenicity of Protein Therapeutics

Because recombinant protein therapeutics are genetically engineered, they have the potential to induce an immunogenic response in a patient.  Immunogenicity risk, as defined by the formation of anti-drug antibodies (ADA),…

Comments Off on Predicting Immunogenicity of Protein Therapeutics
Close Menu